Access Statistics for Paolo Pertile

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 0 1 1 183 0 1 20 396
DRGs: the link between investment in technologies and appropriateness 0 0 0 27 0 0 15 137
Dynamic, economic approaches to HTA under uncertainty 0 0 0 45 0 0 3 175
Dynamic, incentive-compatible contracting for health services 0 0 0 11 1 1 15 25
Dynamic, incentive-compatible contracting for health services 0 1 1 8 0 2 16 30
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 0 2 2 156 2 6 33 426
Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation 0 1 1 59 0 3 10 165
L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC 0 0 0 20 0 2 12 124
Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution 0 0 0 18 0 1 19 173
Optimal sequential sampling rules for the economic evaluation of health technologies 0 0 0 86 0 1 10 261
Pricing policies when patients are heterogeneous: a welfare analysis 0 0 0 17 0 2 7 61
Public finance consolidation and fairness across living generations: the case of Italy 0 0 0 70 0 1 17 203
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 0 0 1 65 0 0 8 113
R&D and market size: who benefits from orphan drug regulation? 0 0 0 76 0 0 12 209
Redistribution at the Local Level: The Case of Public Childcare in Italy 0 0 0 37 0 0 16 148
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 0 3 5 29 2 9 31 97
Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules 0 0 0 40 0 1 5 134
The dynamics of pharmaceutical regulation and R&D investments 0 0 0 77 0 0 12 231
Who should monitor job sick leave? 0 0 0 28 0 1 8 123
Total Working Papers 0 8 11 1,052 5 31 269 3,231


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian decision theoretic model of sequential experimentation with delayed response 0 0 0 3 0 0 8 39
A large scale OLG model for the analysis of the redistributive effects of policy reforms 0 0 0 43 0 2 29 163
A reply to “Who would benefit from average value‐based pricing?” 0 0 1 5 0 0 5 25
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 0 0 0 16 0 1 4 90
Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” 0 0 0 3 1 1 7 35
Investment in Health Technologies in a Competitive Model with Real Options 0 0 0 34 2 2 12 122
Job sick leave: Detecting opportunistic behavior 0 0 0 8 1 1 15 50
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation 0 0 0 9 0 2 9 70
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 0 0 0 18 0 0 9 72
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective 0 0 0 17 0 0 8 74
R&D and market size: Who benefits from orphan drug legislation? 0 0 1 5 1 1 19 50
Redistribution at the local level: the case of public childcare in Italy 0 0 0 4 1 1 10 63
Static and dynamic efficiency of irreversible health care investments under alternative payment rules 0 1 1 22 1 2 14 161
Technology adoption, quality and health care costs: a review of the literature 0 0 0 4 0 0 13 44
The Dynamics of Pharmaceutical Regulation and R&D Investments 0 0 0 10 0 0 10 74
The fiscal disadvantage of young Italians: a new view on consolidation and fairness 0 0 0 33 0 1 20 221
The impact of managed entry agreements on pharmaceutical prices 0 0 1 16 1 1 17 99
The timing of adoption of positron emission tomography: a real options approach 0 0 0 18 0 1 8 95
Two-part payments for the reimbursement of investments in health technologies 0 0 0 13 0 2 15 68
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 0 0 1 10 0 0 4 56
Which valued‐based price when patients are heterogeneous? 0 0 0 12 0 0 5 44
Total Journal Articles 0 1 5 303 8 18 241 1,715


Statistics updated 2026-08-07